Long-Term Specified Drug Use-results Survey of Betanis Tablets

Astellas

Status: Completed

Conditions: Overactive Bladder

Treatments: Drug: Betanis

Study type: Observational

Funder types: Industry

Identifiers

NCT01901120

BE0002

Details and patient eligibility

About

This study is to evaluate the safety and efficacy of long-term use of Betanis (generic name: mirabegron), and to determine the adherence to treatment with mirabegron.

Enrollment: 1,263 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Patients who administer mirabegron for treatment of urinary urgency, daytime frequency, and urgency incontinence associated with overactive bladder and also who have no treatment history of mirabegron.

Trial design

1,263 participants in 1 patient group

Betanis

Description:

the usual adult dosage of mirabegron once daily after a meal

Treatment:

Drug: Betanis